SPECTRAL MEDICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.48 CAD | +6.67% |
|
+9.09% | +12.94% |
| 10/04 | Spectral Medical Updated on Tigris Trial | MT |
| 10/04 | Spectral Medical Brief: Providing Tigris Trial Update; 101 patients enrolled | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 162.6 | 95.83 | 58.94 | 103 | 118.4 | 134.1 | - |
| Enterprise Value (EV) 1 | 162.6 | 95.83 | 58.94 | 103 | 118.4 | 134.1 | 134.1 |
| P/E ratio | -36 x | -10.1 x | -7.33 x | -9.25 x | -7.08 x | -12 x | -24 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 56.7 x | 45.6 x | 28.7 x | 61.8 x | 74.1 x | 95.8 x | 53.6 x |
| EV / Revenue | 56.7 x | 45.6 x | 28.7 x | 61.8 x | 74.1 x | 95.8 x | 53.6 x |
| EV / EBITDA | -41.2 x | -12.4 x | -8.47 x | -14.7 x | -12.2 x | -13.8 x | -34.4 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,25,816 | 2,36,606 | 2,67,886 | 2,78,501 | 2,78,576 | 2,79,394 | - |
| Reference price 2 | 0.7200 | 0.4050 | 0.2200 | 0.3700 | 0.4250 | 0.4800 | 0.4800 |
| Announcement Date | 27/03/20 | 26/03/21 | 24/03/22 | 24/03/23 | 28/03/24 | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.868 | 2.101 | 2.052 | 1.667 | 1.598 | 1.4 | 2.5 |
| EBITDA 1 | -3.947 | -7.757 | -6.955 | -7.025 | -9.723 | -9.7 | -3.9 |
| EBIT | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -4.86 | -9.098 | -8.785 | -11.25 | - | - | - |
| Net income | - | -9.098 | -8.785 | -11.25 | - | - | - |
| Net margin | - | -433.03% | -428.12% | -674.87% | - | - | - |
| EPS 2 | -0.0200 | -0.0400 | -0.0300 | -0.0400 | -0.0600 | -0.0400 | -0.0200 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 27/03/20 | 26/03/21 | 24/03/22 | 24/03/23 | 28/03/24 | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.23 | 0.517 | 0.484 | 0.286 | 0.374 | 0.523 | 0.53 | 0.306 | 0.397 |
| EBITDA | -1.927 | -2.353 | -1.916 | -2.696 | -3.036 | 0.623 | -1.552 | -2.901 | - |
| EBIT 1 | - | - | - | - | - | - | -1.613 | -2.956 | -2.505 |
| Operating Margin | - | - | - | - | - | - | -304.34% | -966.01% | -630.98% |
| Earnings before Tax (EBT) 1 | -2.067 | -2.552 | -2.688 | -2.955 | -3.135 | -2.472 | -1.734 | -3.988 | -3.261 |
| Net income 1 | -2.067 | -2.552 | -2.688 | -2.955 | -3.135 | -2.472 | -1.777 | -3.939 | -3.391 |
| Net margin | -898.7% | -493.62% | -555.37% | -1,033.22% | -838.24% | -472.66% | -335.28% | -1,287.25% | -854.16% |
| EPS 2 | -0.008000 | -0.003000 | -0.0100 | -0.0110 | -0.0120 | -0.007000 | -0.0100 | -0.0100 | -0.0100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/11/21 | 24/03/22 | 13/05/22 | 12/08/22 | 10/11/22 | 24/03/23 | 12/05/23 | 10/08/23 | 09/11/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 0.16 | - | - | - | - | - | - |
| Capex / Sales | 5.61% | - | - | - | - | - | - |
| Announcement Date | 27/03/20 | 26/03/21 | 24/03/22 | 24/03/23 | 28/03/24 | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.48
CAD
Average target price
1.8
CAD
Spread / Average Target
+275.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.94% | 97.97M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- EDT Stock
- Financials Spectral Medical Inc.
